Investor Relations

Recent Event

ANESTHESIOLOGY® 2021

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2020

Email Alerts

Receive updates straight into your inbox

Sign up today

Company Overview

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with central nervous system disorders. The company has five novel and differentiated drug development programs. OLINVYK™ is approved by the FDA. Please see Important Safety Information including Boxed Warning in the full prescribing information available at OLINVYK.com. The company has four investigational drug candidates including TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, TRV045 for diabetic neuropathic pain, and TRV027 for acute respiratory distress syndrome and abnormal clotting in COVID-19 patients.

Investor Contact Information

Company

Trevena, Inc.
955 Chesterbrook Blvd
Suite 110
Chesterbrook, PA 19087
T: (610) 354-8840
ir@trevena.com

Investor Relations

LifeSci Advisors, LLC
Dan Ferry
Managing Director
T: 617-430-7576
daniel@lifesciadvisors.com